Kyverna therapeutics and national institutes of health co-author seminal review on cell therapy for autoimmunity in nature reviews immunology

Promising results from early clinical experience with anti-cd19 car t cells in patients with autoimmune diseases optimal car construct design contributing to an acceptable safety profile, and potential for lasting immune reset are key for treatment adoption  kyverna is currently recruiting for multiple kysa trials where the company's product candidate kyv-101 is used to treat patients suffering from myasthenia gravis, multiple sclerosis, and lupus nephritis emeryville, calif. , june 10, 2024 /prnewswire/ -- kyverna therapeutics, inc. (kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, announced today the publication in nature reviews immunology of a manuscript co-authored with the national institutes of health titled "chimeric antigen receptor t cell therapy for autoimmune disease"1.
CAR Ratings Summary
CAR Quant Ranking